Kaitlyn Bader, Assistant Managing Editor

An AI-powered handheld spectroscopy device is showing promise in improving melanoma detection accuracy among primary care physicians, addressing critical gaps in early diagnosis and timely referral.

The FDA issued 18 warning letters to websites illegally selling unapproved and misbranded botulinum toxin products, citing serious safety risks including botulism-related adverse events.

At the 10th Annual Symposium on Hidradenitis Suppurativa Advances, Ralph George, MD, FRCS, emphasized that the growing collaboration between medical and surgical management is redefining the role of procedures in HS.

At Fall Clinical 2025, Andrew Alexis, MD, reviewed topical, oral, and procedural interventions with patients with melasma and hyperpigmentation, especially in patients with skin of color.

In 2 replicate phase 3 trials, once-daily upadacitinib 15 mg significantly improved total and facial repigmentation in adults and adolescents with non-segmental vitiligo, with a safety profile consistent with prior indications.

According to a poster at Fall Clinical 2025, over 80% of patients remained flare-free across the 2-year period.

At Fall Clinical 2025, Mona Shahriari, MD, presented highlights on the role of IL-13 inhibitors, such as dupilumab, tralokinumab, and lebrikizumab, in managing atopic dermatitis across severities.

At Fall Clinical 2025, Ron Vender, MD, discussed the evolving psoriasis treatment landscape and the persistent challenge of managing palmoplantar pustulosis.

At Fall Clinical 2025, Marc Serota, MD, discussed how GLP-1 therapies, new CSU treatments, and hybrid care models are reshaping dermatologic practice heading into 2026.

At Fall Clinical 2025, Shawn Kwatra, MD, presented insights on managing various cases of chronic itch, as well as understanding the OX40 ligand pathway as the “prequel to inflammation.”

At Fall Clinical 2025, Harrison Nguyen, MD, MBA, MPH, outlined how gene expression profile testing complements traditional staging systems by helping clinicians better identify melanoma and cSCC patients at the highest risk for recurrence.

Data from Fall Clinical 2025 detailed the results from the phase 2 STRIDE and ongoing open-label extension studies demonstrating the efficacy and safety of envudeucitinib, a selective TYK2 inhibitor.

Catch up on coverage from the first day of the 2025 Fall Clinical Dermatology Conference held in Las Vegas, Nevada.

James Del Rosso, DO; April Armstrong, MD, MPH; Mark Nestor, MD, PhD; Mark Lebwohl, MD; Linda Stein Gold, MD; and Darrell Rigel, MD, MS, presented some of the biggest updates in dermatology to close out the year.

The 25th annual meeting begins today and runs through October 26.

Vimal Prajapati, MD, FRCPC, DABD, highlights the durable efficacy of guselkumab, reassuring safety, and quality-of-life improvements in pediatric patients with moderate to severe plaque psoriasis.

Andrew Mastro, MS, PA-C, moderated a recent Dermatology Times Case-Based Roundtable event to present 3 complex cases of moderate to severe psoriasis treated with biologics.

Vimal Prajapati, MD, FRCPC, DABD, highlights guselkumab’s ability to achieve high levels of skin clearance in pediatric patients with moderate to severe plaque psoriasis.

During a Case-Based Roundtable event, Naiem Issa, MD, PhD, guided colleagues through 3 complex atopic dermatitis cases, highlighting how modern topicals can deliver rapid and durable control across age groups.

Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS, discusses Apex Skin’s mission to make research more representative and accessible through integrated, multisite dermatology practices.

Spesolimab joins LEO Pharma’s dermatology portfolio to further expand spesolimab’s reach for patients worldwide with generalized pustular psoriasis.

Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS, shares how Apex Skin is improving trial adherence through bilingual staff, modernizing operations with digital tools, and strengthening community partnerships.

Mary W. Chang, MD, discusses the expanded FDA approval of ruxolitinib cream for children with atopic dermatitis and its role in addressing treatment gaps, safety, and real-world use.

Phase 3 PROTOSTAR data support new indications, expanding treatment options for children impacted by chronic immune-mediated diseases.

Derm Dispatch host Renata Block, DMSc, MMS, PA-C, and Buchi Neita, MCMSc, PA-C, discuss how to revolutionize dermatology with lifestyle medicine, enhancing skin health and overall well-being.

TRIV-509 is a dual KLK5/7 inhibitor that aims to address barrier dysfunction, inflammation, and itch in moderate to severe AD.

Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS, shares how Apex Skin’s multi-site model advances clinical trial access, diversity, and execution.

Todd Schlesinger, MD, FAAD, FASMS, moderated an engaging discussion with colleagues to discuss complex vitiligo cases during a Dermatology Times Case-Based Roundtable event.

Phase 1a results showing STAR-0310’s half-life of up to 68 days, durable cytokine inhibition, and a favorable safety profile will be presented in full at EADV 2025.